TNF Pharmaceuticals shareholders approve 5x increase in authorized common shares and reverse split authorization

Q/C TECHNOLOGIES, INC.

Authorized common shares increased from 250M to 1.25B, filed June 6, 2025.
Stockholders approved reverse stock split at ratio 1-for-2 to 1-for-100, board discretion, within one year.
Series F and F-1 preferred stock stated value increased from $1,000 to $1,100 per share, board may increase up to $1,250.
All six director nominees elected; auditor ratification approved.
Voting results: ~6.3M for share increase, ~6.4M for reverse split.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Q/C TECHNOLOGIES, INC.: Increased authorized common stock from 250,000,000 to 1,250,000,000 shares and corresponding change to total authorized capital stock (effective 2025-06-06).

Change: charter amendment
Effective: 2025-06-06

Exact text from the filing

On June 3, 2025, TNF Pharmaceuticals, Inc. (the “Company”) reconvened its 2025 annual meeting of stockholders, which was adjourned from May 20, 2025 (the “Annual Meeting”). At the Company’s Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Share Increase Amendment”) to increase the number of authorized shares of common stock, par value $0.001 per share (“Common Stock”), from 250,000,000 shares to 1,250,000,000 and to make a corresponding change to the number of authorized shares of the Company’s capital stock. Following the Annual Meeting, on June 6, 2025, the Company filed the Share Increase Amendment with the Secretary of State of the State of Delaware.

View on SEC.gov

Browse all governance changes →

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-014103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.